DE69110877D1 - Idiotypen-impfung gegen b-zell-lymphoma. - Google Patents

Idiotypen-impfung gegen b-zell-lymphoma.

Info

Publication number
DE69110877D1
DE69110877D1 DE69110877T DE69110877T DE69110877D1 DE 69110877 D1 DE69110877 D1 DE 69110877D1 DE 69110877 T DE69110877 T DE 69110877T DE 69110877 T DE69110877 T DE 69110877T DE 69110877 D1 DE69110877 D1 DE 69110877D1
Authority
DE
Germany
Prior art keywords
idiotype
dendritic cells
pulsed
cells
cell lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69110877T
Other languages
English (en)
Other versions
DE69110877T2 (de
Inventor
Heribert Bohlen
Jacques Urbain
Camp Benjamin Van
Kristiaan Thielemans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Original Assignee
Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23960532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69110877(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Response Corp filed Critical Immune Response Corp
Application granted granted Critical
Publication of DE69110877D1 publication Critical patent/DE69110877D1/de
Publication of DE69110877T2 publication Critical patent/DE69110877T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69110877T 1990-03-14 1991-03-13 Idiotypen-impfung gegen b-zell-lymphoma. Expired - Fee Related DE69110877T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/493,511 US20030072751A1 (en) 1990-03-14 1990-03-14 Idiotypic vaccination against b cell lymphoma
PCT/US1991/001683 WO1991013632A1 (en) 1990-03-14 1991-03-13 Idiotypic vaccination against b cell lymphoma

Publications (2)

Publication Number Publication Date
DE69110877D1 true DE69110877D1 (de) 1995-08-03
DE69110877T2 DE69110877T2 (de) 1995-11-16

Family

ID=23960532

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69110877T Expired - Fee Related DE69110877T2 (de) 1990-03-14 1991-03-13 Idiotypen-impfung gegen b-zell-lymphoma.

Country Status (12)

Country Link
US (1) US20030072751A1 (de)
EP (1) EP0521897B1 (de)
JP (1) JP2735947B2 (de)
AT (1) ATE124265T1 (de)
AU (1) AU645552B2 (de)
CA (1) CA2078235C (de)
DE (1) DE69110877T2 (de)
DK (1) DK0521897T3 (de)
ES (1) ES2074268T3 (de)
FI (1) FI105452B (de)
NO (1) NO308509B1 (de)
WO (1) WO1991013632A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
JP3649335B2 (ja) * 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
WO1993020185A1 (en) * 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
EP1421947A1 (de) * 1992-07-22 2004-05-26 The Trustees Of Princeton University P53 vakzine
DE69331703D1 (de) * 1992-08-21 2002-04-18 Us Gov Health & Human Serv B-lymphomazellinie und antigen
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
AU710783B2 (en) * 1994-06-14 1999-09-30 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo T cell activation by antigen-pulsed dendritic cells
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1997022349A1 (en) * 1995-12-20 1997-06-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
AU2872199A (en) 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
WO2000062818A1 (en) 1999-04-20 2000-10-26 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Also Published As

Publication number Publication date
AU7488691A (en) 1991-10-10
ATE124265T1 (de) 1995-07-15
DE69110877T2 (de) 1995-11-16
FI105452B (fi) 2000-08-31
DK0521897T3 (da) 1995-11-13
FI924082A0 (fi) 1992-09-11
WO1991013632A1 (en) 1991-09-19
JP2735947B2 (ja) 1998-04-02
NO923542L (no) 1992-09-11
CA2078235A1 (en) 1991-09-15
ES2074268T3 (es) 1995-09-01
AU645552B2 (en) 1994-01-20
EP0521897A1 (de) 1993-01-13
CA2078235C (en) 2004-01-20
JPH05507905A (ja) 1993-11-11
US20030072751A1 (en) 2003-04-17
NO923542D0 (no) 1992-09-11
EP0521897B1 (de) 1995-06-28
FI924082A (fi) 1992-09-11
NO308509B1 (no) 2000-09-25

Similar Documents

Publication Publication Date Title
ATE124265T1 (de) Idiotypen-impfung gegen b-zell-lymphoma.
DK0669836T3 (da) Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
MX9203439A (es) Una citocina mamifera, il-11
DE69418699D1 (de) Induktion der antworten zytotoxischer t-lymphozyten
FR2620941B1 (fr) Vaccin contenant des adjuvants et des antigenes tumoraux
DK0474727T3 (da) HER2 ekstracellulært domæne
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
FI913275A0 (fi) Foerfarande foer foerbaettring av sjukdomsmottstaondskraft.
ATE231184T1 (de) Impfstoffe gegen die pest
CA2033640A1 (en) Vaccines against cancer and infectious diseases
IT8709354A0 (it) Siringa per iniezioni,in specie endovenose,realizzata per poteressere usata una sola volta,senza possibilita' di riaspirazione.
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
KR890700659A (ko) 항원-특이적 t세포주의 생성방법 및 이의 치료적 용도
DK1021196T3 (da) Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
IT8024091A0 (it) Dispositivo di comando per determinare l'istante di accensione e dosare il carburante per un motore endotermico.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
IT8050422A0 (it) Dispositivo per la riduzione delle vibrazioni di motori in particolare di motori endotermici ad iniezione
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
GR3021983T3 (en) Cross-reactive influenza a immunization
ATE175357T1 (de) Empfängnisverhütender impfstoff
Baenkler Autoimmunity in infectious diseases.
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
IT1229943B (it) Procedimento e dispositivo di misura dell'anticipo di inizio mandata dell'iniezione, particolarmente in motori diesel
UA11418A1 (uk) Пристрій для введеhhя лікарських препаратів твариhам hа відстаhі
SU681928A1 (ru) Адъювант

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee